In Vitro Effects of Melarsoprol on Cells From Patients With B-CLL
| Patient No. . | Day . | Mean Viability (%) . | ||||
|---|---|---|---|---|---|---|
| . | . | Control . | MEL 5 × 10−7 mol/L . | MEL 10−7 mol/L . | MEL 10−8 mol/L . | MEL 10−9 mol/L . |
| 1 | 1 | 83 ± 5 | 48 ± 6 | 74 ± 9 | 77 ± 2 | 66 ± 1 |
| 2 | 94 ± 1 | 52 ± 3 | 73 ± 4 | 74 ± 4 | 75 ± 6 | |
| 3 | 82 ± 5 | 43 ± 7 | 55 ± 3 | 73 ± 1 | 70 ± 4 | |
| 4 | 84 ± 4 | 49 ± 5 | 58 ± 7 | 66 ± 3 | 82 ± 7 | |
| 2 | 1 | 90 ± 2 | 59 ± 1 | 68 ± 9 | 81 ± 8 | 86 ± 2 |
| 2 | 90 ± 3 | 43 ± 8 | 66 ± 6 | 63 ± 7 | 78 ± 6 | |
| 3 | 91 ± 6 | 49 ± 11 | 64 ± 1 | 72 ± 3 | 77 ± 6 | |
| 4 | 77 ± 5 | 57 ± 17 | 48 ± 2 | 62 ± 13 | 64 ± 3 | |
| 3 | 1 | 87 ± 10 | 66 ± 7 | 82 ± 2 | 78 ± 7 | 79 ± 2 |
| 2 | 90 ± 2 | 57 ± 11 | 68 ± 8 | 74 ± 7 | 74 ± 7 | |
| 3 | 86 ± 8 | 59 ± 5 | 55 ± 6 | 53 ± 5 | 68 ± 2 | |
| 4 | 84 ± 4 | 41 ± 9 | 45 ± 6 | 52 ± 7 | 44 ± 11 | |
| 4 | 1 | 99 ± 2 | 65 ± 4 | 58 ± 7 | 68 ± 3 | 84 ± 4 |
| 2 | 87 ± 7 | 51 ± 1 | 52 ± 6 | 57 ± 4 | 69 ± 5 | |
| 3 | 71 ± 3 | 34 ± 3 | 41 ± 1 | 50 ± 11 | 48 ± 5 | |
| 4 | 64 ± 2 | 40 ± 4 | 30 ± 11 | 46 ± 3 | 46 ± 12 | |
| 5 | 1 | 86 ± 6 | 54 ± 2 | 57 ± 5 | 80 ± 11 | 82 ± 2 |
| 2 | 90 ± 3 | 47 ± 2 | 42 ± 9 | 54 ± 11 | 60 ± 8 | |
| 3 | 88 ± 4 | 55 ± 10 | 42 ± 6 | 51 ± 7 | 63 ± 8 | |
| 4 | 82 ± 7 | 46 ± 11 | 33 ± 9 | 51 ± 8 | 43 ± 11 | |
| Patient No. . | Day . | Mean Viability (%) . | ||||
|---|---|---|---|---|---|---|
| . | . | Control . | MEL 5 × 10−7 mol/L . | MEL 10−7 mol/L . | MEL 10−8 mol/L . | MEL 10−9 mol/L . |
| 1 | 1 | 83 ± 5 | 48 ± 6 | 74 ± 9 | 77 ± 2 | 66 ± 1 |
| 2 | 94 ± 1 | 52 ± 3 | 73 ± 4 | 74 ± 4 | 75 ± 6 | |
| 3 | 82 ± 5 | 43 ± 7 | 55 ± 3 | 73 ± 1 | 70 ± 4 | |
| 4 | 84 ± 4 | 49 ± 5 | 58 ± 7 | 66 ± 3 | 82 ± 7 | |
| 2 | 1 | 90 ± 2 | 59 ± 1 | 68 ± 9 | 81 ± 8 | 86 ± 2 |
| 2 | 90 ± 3 | 43 ± 8 | 66 ± 6 | 63 ± 7 | 78 ± 6 | |
| 3 | 91 ± 6 | 49 ± 11 | 64 ± 1 | 72 ± 3 | 77 ± 6 | |
| 4 | 77 ± 5 | 57 ± 17 | 48 ± 2 | 62 ± 13 | 64 ± 3 | |
| 3 | 1 | 87 ± 10 | 66 ± 7 | 82 ± 2 | 78 ± 7 | 79 ± 2 |
| 2 | 90 ± 2 | 57 ± 11 | 68 ± 8 | 74 ± 7 | 74 ± 7 | |
| 3 | 86 ± 8 | 59 ± 5 | 55 ± 6 | 53 ± 5 | 68 ± 2 | |
| 4 | 84 ± 4 | 41 ± 9 | 45 ± 6 | 52 ± 7 | 44 ± 11 | |
| 4 | 1 | 99 ± 2 | 65 ± 4 | 58 ± 7 | 68 ± 3 | 84 ± 4 |
| 2 | 87 ± 7 | 51 ± 1 | 52 ± 6 | 57 ± 4 | 69 ± 5 | |
| 3 | 71 ± 3 | 34 ± 3 | 41 ± 1 | 50 ± 11 | 48 ± 5 | |
| 4 | 64 ± 2 | 40 ± 4 | 30 ± 11 | 46 ± 3 | 46 ± 12 | |
| 5 | 1 | 86 ± 6 | 54 ± 2 | 57 ± 5 | 80 ± 11 | 82 ± 2 |
| 2 | 90 ± 3 | 47 ± 2 | 42 ± 9 | 54 ± 11 | 60 ± 8 | |
| 3 | 88 ± 4 | 55 ± 10 | 42 ± 6 | 51 ± 7 | 63 ± 8 | |
| 4 | 82 ± 7 | 46 ± 11 | 33 ± 9 | 51 ± 8 | 43 ± 11 | |
Numbers represent the mean and standard deviation evaluated in triplicate.
Abbreviation: MEL, melarsoprol.